Literature DB >> 12531340

Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.

Paolo Bonanni1, Giovanna Pesavento, Angela Bechini, Emilia Tiscione, Francesco Mannelli, Cristiana Benucci, Antonella Lo Nostro.   

Abstract

Ten years have elapsed since routine vaccination of infants and of 12-year-old adolescent was implemented in Italy. In this period, evidence has accumulated on the epidemiological impact of universal immunisation. Coverage is on average >90% and is >or=95% in many areas of the country. Incidence of acute hepatitis B, that was already declining before 1991, was further decreased by routine vaccination programmes. This is particularly evident in adolescents and young adults (cohorts involved by mandatory vaccination), while incidence shows little changes in older subjects according to data of the last years. Prevalence of hepatitis B virus (HBV) markers detected by sero-epidemiological studies on anonymous sera confirms both the very high coverage with hepatitis B vaccination and the virtual absence of chronic HBsAg carriers in cohorts involved by routine vaccination programmes. The system of passive surveillance on adverse events following hepatitis B vaccination supports the excellent safety record of hepatitis B vaccines. In a hyperendemic area of Southern Italy, where a pilot programme was firstly implemented, it was also possible to document the decline of the involvement of hepatitis B in chronic liver pathologies (from 48% in 1982 to 18% in 1997). If coverage rates are maintained at the present levels, elimination of HBV transmission in Italy may be envisaged in few decades.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531340     DOI: 10.1016/s0264-410x(02)00580-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Unsolved problems and future perspectives of hepatitis B virus vaccination.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

2.  A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium.

Authors:  Sophie Quoilin; Veronik Hutse; Hans Vandenberghe; Françoise Claeys; Els Verhaegen; Liesbet De Cock; Frank Van Loock; Geert Top; Pierre Van Damme; Robert Vranckx; Herman Van Oyen
Journal:  Eur J Epidemiol       Date:  2007-03-14       Impact factor: 8.082

3.  Need to take special care of non-responders to hepatitis B vaccination among health-care workers, students and chronic patients.

Authors:  Angela Bechini; Paolo Bonanni; Maddalena Grazzini; Diana Paolini; Giulio Arcangeli; Nicola Mucci; Costanza Bini; Emilia Tiscione; Beatrice Zanella; Sara Boccalini
Journal:  Hum Vaccin Immunother       Date:  2020-12-03       Impact factor: 3.452

Review 4.  Prevention of hepatitis B virus infection: from the past to the future.

Authors:  R Orlando; M Foggia; A E Maraolo; S Mascolo; G Palmiero; O Tambaro; G Tosone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-13       Impact factor: 3.267

5.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

6.  The prevalence of hepatitis B virus markers in a cohort of students in Bangui, Central African Republic.

Authors:  Narcisse P Komas; Souleyman Baï-Sepou; Alexandre Manirakiza; Josiane Léal; Aubin Béré; Alain Le Faou
Journal:  BMC Infect Dis       Date:  2010-07-29       Impact factor: 3.090

7.  Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.

Authors:  Sara Boccalini; Elettra Pellegrino; Emila Tiscione; Giovanna Pesavento; Angela Bechini; Miriam Levi; Stefano Rapi; Stefano Mercurio; Francesco Mannelli; Marta Peruzzi; Cesare Berardi; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-25       Impact factor: 3.452

Review 8.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

9.  Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.

Authors:  James W Keck; Lisa R Bulkow; Gregory A Raczniak; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

Review 10.  Tumour virus vaccines: hepatitis B virus and human papillomavirus.

Authors:  Margaret Stanley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.